Peptide-Based PET Scan Finds Insulin-Producing Tumors With 94% Sensitivity, Beating Standard Methods
An Exendin-4-based PET/CT scan detected insulinomas with 94% sensitivity and 96% accuracy, significantly outperforming all conventional and molecular imaging methods.
Quick Facts
What This Study Found
In 47 patients with biochemically proven hyperinsulinemic hypoglycemia, the peptide-based tracer 68Ga-NOTA-Exendin-4 PET/CT achieved 94.11% sensitivity and 95.74% accuracy for localizing insulinomas — significantly outperforming 68Ga-DOTATATE PET/CT (70.59% sensitivity, p=0.026), 18F-FDG PET/CT (50.00% sensitivity), and conventional imaging (CE-CT/CE-MRI).
Exendin-4 PET/CT also showed better imaging quality and easier interpretation than the other molecular imaging methods. Combining Exendin-4 and DOTATATE PET/CT could provide comprehensive evaluation of insulinomas.
Key Numbers
How They Did This
A prospective study of 47 patients with biochemically confirmed endogenous hyperinsulinemic hypoglycemia. All patients underwent 68Ga-NOTA-Exendin-4 PET/CT alongside other imaging methods (68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CE-CT, CE-MRI). Sensitivity and accuracy were calculated at both patient and lesion levels. Both experienced (>10 years) and junior radiologists interpreted the scans to assess interpretability.
Why This Research Matters
Insulinomas are rare pancreatic tumors that cause dangerous low blood sugar. Finding them before surgery is critical but difficult — conventional imaging often misses them. This peptide-based imaging approach nearly doubles the detection rate compared to standard PET tracers, potentially transforming how these tumors are located and treated.
The Bigger Picture
This study demonstrates a powerful application of peptide science beyond therapy — using peptides as precision diagnostic tools. The GLP-1 receptor, which is the target of blockbuster weight loss drugs like semaglutide, is leveraged here for its high expression on insulinoma cells to create a molecular beacon that lights up these hard-to-find tumors on PET scans.
What This Study Doesn't Tell Us
Relatively small sample of 47 patients, though insulinomas are rare. The study was retrospectively registered on ClinicalTrials.gov. 68Ga-NOTA-Exendin-4 is not yet widely available, limiting immediate clinical applicability. Results may not generalize to malignant insulinomas, as the study focused on benign tumors.
Questions This Raises
- ?Could Exendin-4 PET/CT become the standard first-line imaging for suspected insulinoma?
- ?Does this peptide-based imaging approach work for detecting malignant or metastatic insulinomas?
- ?Could similar GLP-1 receptor-targeted tracers be developed for other GLP-1R-expressing tumors?
Trust & Context
- Key Stat:
- 94.1% sensitivity The Exendin-4 PET/CT detected insulinomas in 94.1% of patients, compared to just 50% for standard FDG-PET and 70.6% for DOTATATE PET — a transformative improvement for this challenging diagnosis.
- Evidence Grade:
- This is a prospective comparative study with head-to-head testing of multiple imaging modalities in the same patients, providing strong diagnostic accuracy evidence. However, the sample size of 47 is modest.
- Study Age:
- Published in 2025, this is a very recent study advancing the clinical application of peptide-based molecular imaging.
- Original Title:
- Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.
- Published In:
- European journal of nuclear medicine and molecular imaging, 52(11), 4102-4111 (2025)
- Authors:
- Yu, Haonan, Bao, Xiangyuan, Gu, Yian, Pan, Meijie, He, Qing, Li, Dong, Chen, Qiusong, Yao, Shaobo
- Database ID:
- RPEP-14402
Evidence Hierarchy
Frequently Asked Questions
What is Exendin-4 and how does it help find insulinomas?
Exendin-4 is a peptide that binds to GLP-1 receptors, which are highly expressed on insulinoma tumor cells. When attached to a radioactive tracer and injected, it homes in on these tumors and makes them visible on PET/CT scans — essentially using the tumor's own receptor expression as a beacon.
Why are insulinomas so hard to find with regular imaging?
Insulinomas are typically small (often under 2 cm) and located deep in the pancreas. Standard CT, MRI, and even conventional PET scans miss a significant percentage of them. Exendin-4 PET/CT targets the specific receptors on these tumors, detecting them even when they're small.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14402APA
Yu, Haonan; Bao, Xiangyuan; Gu, Yian; Pan, Meijie; He, Qing; Li, Dong; Chen, Qiusong; Yao, Shaobo. (2025). Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.. European journal of nuclear medicine and molecular imaging, 52(11), 4102-4111. https://doi.org/10.1007/s00259-025-07288-x
MLA
Yu, Haonan, et al. "Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.." European journal of nuclear medicine and molecular imaging, 2025. https://doi.org/10.1007/s00259-025-07288-x
RethinkPeptides
RethinkPeptides Research Database. "Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOT..." RPEP-14402. Retrieved from https://rethinkpeptides.com/research/yu-2025-comparison-of-petct-using
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.